Spots Global Cancer Trial Database for braf mutant
Every month we try and update this database with for braf mutant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | NCT05668585 | Solid Tumors Melanoma NSCLC CRC ATC | CFT1946 Trametinib Cetuximab | 18 Years - | C4 Therapeutics, Inc. | |
| S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer | NCT02164916 | Colorectal Canc... | cetuximab irinotecan hydr... vemurafenib | 18 Years - | SWOG Cancer Research Network | |
| A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma | NCT01227889 | Cancer | GSK2118436 Dacarbazine (DT... | 18 Years - | GlaxoSmithKline | |
| A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma | NCT01227889 | Cancer | GSK2118436 Dacarbazine (DT... | 18 Years - | GlaxoSmithKline | |
| S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer | NCT02164916 | Colorectal Canc... | cetuximab irinotecan hydr... vemurafenib | 18 Years - | SWOG Cancer Research Network | |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | NCT01726738 | Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel... | BRAF inhibitor ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer | NCT02380443 | Colorectal Canc... | AlloStim Cryoablation | 18 Years - 80 Years | Immunovative Therapies, Ltd. | |
| AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer | NCT02380443 | Colorectal Canc... | AlloStim Cryoablation | 18 Years - 80 Years | Immunovative Therapies, Ltd. | |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | NCT01726738 | Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel... | BRAF inhibitor ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | NCT01726738 | Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel... | BRAF inhibitor ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
